We expect EBIT of NOK 199m, -28% vs consensus. Key risk is prices amid downgrades and weak biology. Tides to turn; '24e-'25e P/E 14x-9x. BUY, TP NOK 75.
Quality downgrades partly offset stronger spot prices, so our Q1 estimates are up only 3% ahead of the trading updates. Consensus a tad optimistic – we are still 6% below on Q1 EBIT.
We expect clean EBIT of EUR 232m, -16% vs. consensus. Key risk is price realisation amid downgrades overload. Valuation support at '24e P/E of 12x; BUY, TP NOK 229.
We expect EBIT of NOK 1,899m, +4% vs consensus. Relatively high VAP capacity, but downgrades will still hurt. +20% YTD and '24e-'25e P/E of 17x-15x gives more muted r/r.
We expect EBIT of NOK 783m, -6% vs consensus. Key risk is prices (i.e., downgrade share and trout volume). Attractive at '24e-'25e P/E of 10x-9x. BUY, TP of NOK 59.
'24e EBIT (core) -22% on volume cut and higher costs. Significant growth potential once biology normalises, and it can't get much worse. Risk/reward is positive. BUY.
'24e EBIT down 4% on temporary issues in North. Best-in-class farmer with significant growth potential. Warranted premium to peers; BUY, TP of NOK 687 (645).
We keep our '24-'25 estimates largely unchanged. Another record year in the making amid strong outlook. '24e P/E at 11x, a 15% discount to peers and 7-8% yield: BUY.
Higher salmon prices as biology goes from bad to worse, but muted '24e EBIT impact; flipside is volumes down and costs up. The playing field is changing, but we remain sector BUYers.